The following represent areas where HBOT has the strongest clinical evidence — backed by randomised controlled trials, systematic reviews, and meta-analyses published in peer-reviewed journals.
✓ FDA Approved
Chronic Non-Healing Wounds
Chronic wounds — including diabetic foot ulcers, venous stasis ulcers, and post-radiation injuries — are among the most robustly evidenced indications for HBOT. By flooding oxygen-depleted tissue, HBOT stimulates the fibroblast activity, collagen synthesis, and angiogenesis essential for wound closure.
81%
of chronic non-healing wounds achieved near-complete or complete healing after HBOT in a study of 248 patients referred after failing standard wound care
Teguh et al., Wound Repair and Regeneration, 2021 (Amsterdam UMC / Reinier de Graaf Hospital)
✓ FDA Approved
Diabetic Foot Ulcers & Limb Salvage
Diabetic foot ulcers occur in approximately 15% of all patients with diabetes and are the leading cause of non-traumatic lower-limb amputation. Two in three amputations in this population are diabetes-related. HBOT, used adjunctively with standard wound care, significantly reduces major amputation risk in Wagner Grade 3+ ulcers.
RR 0.60
relative risk of major amputation with adjunctive HBOT versus standard care alone — approximately a 40% reduction — across 768 patients in 14 controlled trials (95% CI 0.39–0.92)
Santema et al., Scientific Reports, 2021 (systematic review & meta-analysis, 14 trials, 768 patients); StatPearls (NCBI), 2023
Emerging Evidence
Traumatic Brain Injury & Post-Concussion Syndrome
HBOT has been applied to chronic TBI since 1989. Elevated dissolved oxygen penetrates deep into damaged brain tissue, promoting angiogenesis and neurogenesis in areas starved of perfusion. A 2025 systematic review and meta-analysis of 250 patients found statistically significant improvements across all neurocognitive domains measured.
+7.47
mean difference in general cognitive scores post-HBOT vs baseline, with memory, attention, executive function, and motor skills all significantly improved (p < 0.003)
Systematic Review & Meta-Analysis, Annals of Medicine and Surgery, Sept 2025 (250 patients, 4 studies); conference abstract also presented in Neurology, April 2025
✓ FDA Approved · First-Line
Carbon Monoxide Poisoning
Carbon monoxide displaces oxygen from haemoglobin with an affinity 200–250× greater than oxygen. HBOT is the gold-standard, first-line emergency treatment — rapidly saturating plasma with dissolved oxygen independent of haemoglobin, slashing the half-life of carboxyhaemoglobin from approximately 4–5 hours breathing room air to approximately 20–23 minutes at 3 ATA, and dramatically reducing the risk of delayed neurological sequelae.
~20 min
COHb half-life at 3 ATA HBOT versus 4–5 hours breathing room air — more than a 12× acceleration in CO elimination (normobaric 100% O₂ reduces it to ~60–90 min; HBOT reduces it further to ~20–23 min)
StatPearls / NCBI — Carbon Monoxide Toxicity; Clinician.com review; Polish Medical Society Position Statement, PMC 2025; UHMS Indications Reference, 2020
✓ FDA Approved
Delayed Radiation Injury
Radiation-induced tissue damage — occurring months or years after cancer treatment — causes progressive hypoxia, fibrosis, and necrosis in affected bone and soft tissue. HBOT reverses this cycle by restoring oxygen gradients, stimulating neovascularisation, and supporting tissue regeneration.
84%
of 602 patients treated with HBOT for radiation-induced haemorrhagic cystitis achieved partial or complete resolution, across a scoping review and meta-analysis; individual study ranges span 60–92%
Cardinal et al., Current Urology Reports, 2018 (scoping review & meta-analysis, 602 patients); supported by Yang et al., Journal of Clinical Medicine, 2024 (556 patients, 89.9% symptom improvement)
Active Research
PTSD & Neuropsychiatric Sequelae
Multiple trials of HBOT for mild TBI have simultaneously demonstrated improvement in PTSD symptoms, prompting dedicated investigation. fMRI data shows measurable increases in BOLD signal in the dorsolateral prefrontal cortex, hippocampus, and thalami following treatment. A 2024 systematic review and dosage analysis found meaningful symptomatic improvement in both military and civilian cohorts.
r = 0.42–0.67
correlation between fMRI BOLD signal changes in peak regions and percent change in PTSD symptom scores (CAPS), confirming objective neurobiological response
Andrews & Harch, Frontiers in Neurology, 2024
The Oxygen-Wound Connection
All wounds are physiologically hypoxic. In pathological states — peripheral arterial disease, diabetes, radiation injury — oxygen tension at the wound site can fall to half or less of the value seen in healthy surrounding tissue. Every key component of wound healing — fibroblast replication, collagen deposition, angiogenesis, and leukocyte bactericidal killing — is oxygen-dependent.
HBOT addresses this directly. Rather than simply restoring normoxia, it creates a sustained period of supraphysiologic oxygen tension that drives healing cascades far beyond what ambient air can achieve.
Source: UHMS Clinical Indications Reference, 2020; Wound Repair and Regeneration literature, Teguh et al., 2021
248
patients with chronic wounds referred after failing standard care — 81% achieved near-complete or complete healing with HBOT
74%
positive predictive value of a TcpO₂ >200 mmHg during HBOT for predicting wound healing or limb salvage (UHMS, 2020)
15%
lifetime prevalence of diabetic foot ulcer among people living with diabetes — the principal driver of non-traumatic amputation globally
